Can erythropoietin therapy improve survival?

Oncology

Volumn 67, Issue SUPPL. 1, 2004, Pages 5-11

  Glaspya, John ^a   Dunstb, Juergen ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Anaemia; Cancer; Disease progression; Epoetin; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TAMOXIFEN;

ANEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; FOLLOW UP; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN DETERMINATION; HUMAN; LUNG CANCER; LYMPHOMA; MEDICAL RESEARCH; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK FACTOR; SOLID TUMOR; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; TUMOR GROWTH; UTERINE CERVIX CANCER;

ANEMIA, HYPOCHROMIC; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; META-ANALYSIS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE;

EID: 5644247335     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080705     Document Type: Conference Paper

References (29)

1. Ludwig H, Birgegard G, Olmi P, Nortier J: European Cancer Anaemia Survey (ECAS): prospective evaluation of anemia in over 15 000 cancer (CA) patients. Ann Oncol 2002; 13(suppl 5):169(abstract 623PD).
2. Albain KS, Crowley JJ, LeBlanc M, Livingston RB: Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-1626.
3. Robnett TJ, Machtay M, Hahn SM, Shrager JB, Friedberg JS, Kaiser LR: Pathological response to preoperative chemoradiation worsens with anemia in non-small cell lung cancer patients. Cancer J 2002;8:263-267.
4. Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, Koelbl H, Haensgen G: Anemia in cervical cancer: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 2003;56:778-787.
5. Van Belle SJ, Cocquyt V: Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol/Hematol 2003;47:1-11.
6. Caro JJ, Salas M, Ward A, Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 2001;91:2214-2221.
7. Vaupel P, Briest S, Höckel M: Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wien Med Wochenschr 2002;152:334-342.
8. Teicher BA, Holden SA, al-Achi A, Herman TS: Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSallC murine fibrosarcoma. Cancer Res 1990;50:3339-3344.
9. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
10. Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
11. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
12. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J; Aranesp 980297 Study Group: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
13. Pirker R, Vansteenkiste J, Gateley J, Tomita D, Rossi G, Musil J: Results of a phase 3, randomized, double-blind study indicate that darbepoetin alfa decreases RBC transfusions and increases health-related quality of life in comparison with placebo. Hematol J 2002;3(suppl 1):352(abstract 1189).
14. Glaser CM, Millesi W, Kornek GV, Lang S, Schüll B, Watzinger F, Selzer E, Lavey RS: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiation Oncol Biol Phys 2001;50:705-715.
15. Blohmer JU, Wurschmidt F, Petry U, Weise G, Sehouli J, Kimmig R, Dressler, Kentenich, Kohls A, Lichtenegger W: 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: Sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for pts with high-risk cervical cancer. Proc Am Soc Clin Oncol 2003;22:abstract 1798.
16. Antonadou D, Cardamakis E, Puglisi M, Malamos N, Throuvalas N: Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Eur J Cancer 2001;37 (suppl 6):S144(abstract 530).
17. Dunst J: Erythropoietin and radiotherapy: a dangerous combination? Strahlenther Onkol 2004;180:133-135.
18. Leyland-Jones B, Mahmud S: Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:80.
19. Vaupel P, Mayer A: Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:992.
20. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennet C, Engert A: Erythropoietin for patients with malignant disease (Cochrane Review). In: The Cochrane Library, Issue 3, Chichester, John Wiley & Sons, 2004.
21. Aapro M, Dunst J, Morère J-F, Nowrousian M, Huber M, Burger H-U: Effect of epoetin beta on tumour progression and survival in patients with cancer: a meta-analysis of controlled clinical studies. Ann Oncol 2004;15(suppl 3):abstract 841P.
22. Lee AY, Levine MN: Venous thromboembolism and cancer: Risks and outcomes. Circulation 2003;107(suppl 1):I17-I21.
23. Bick RL: Cancer-associated thrombosis. N Engl J Med 2003;349:109-111.
24. Wun T, Law L, Harvey D, Sieracki B, Scudder SA, Ryu JK: Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003;98:1514-1520.
25. Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM: The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 2004;27:185-190.
26. Coiffier B, Boogaerts M, Aapro M, Huber M, Burger H-U: Thromboembolic events in patients with cancer treated with epoetin beta: A meta-analysis of controlled clinical trials. Ann Oncol 2004;15(suppl 3):abstract 840P.
27. Österborg A, Brandberg Y, Hedenus M: Impact of rhuepo (epoetin beta) on survival of patients with lymphoproliferative malignancies: Longterm follow-up of a large randomised study. Hematol J 2004;5(suppl 2):S190(abstract 556).
28. Österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D; Epoetin Beta Hematology Study Group: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-2494.
29. Aapro M, San Miguel J: Evolving treatment strategies for anaemia in cancer: experience with epoetin beta. Oncology 2004;67(suppl 1):17-22.